Plasma phosphorylated tau 181 predicts ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function.
Auteur(s) :
Lehmann, S. [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Schraen, Susanna [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Vidal, J. S. [Auteur]
AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
Delaby, C. [Auteur]
Blanc, F. [Auteur]
Paquet, C. [Auteur]
Allinquant, B. [Auteur]
Bombois, S. [Auteur]
Gabelle, A. [Auteur]
Hanon, O. [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Hôpital Saint Eloi [CHU Montpellier]
Schraen, Susanna [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Vidal, J. S. [Auteur]
AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
Delaby, C. [Auteur]
Blanc, F. [Auteur]
Paquet, C. [Auteur]
Allinquant, B. [Auteur]
Bombois, S. [Auteur]
Gabelle, A. [Auteur]
Hanon, O. [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Titre de la revue :
Journal of Neurology, Neurosurgery and Psychiatry
Numéro :
94
Date de publication :
2023-04-03
ISSN :
1468-330X
Mot(s)-clé(s) :
dementia
alzheimer's disease
biochemistry
alzheimer's disease
biochemistry
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Objectives Plasma P-tau181 is an increasingly established diagnostic marker for Alzheimer’s disease (AD). Further validation in prospective cohorts is still needed, as well as the study of confounding factors that could ...
Lire la suite >Objectives Plasma P-tau181 is an increasingly established diagnostic marker for Alzheimer’s disease (AD). Further validation in prospective cohorts is still needed, as well as the study of confounding factors that could influence its blood level. Methods This study is ancillary to the prospective multicentre Biomarker of AmyLoid pepTide and AlZheimer’s diseAse Risk cohort that enrolled participants with mild cognitive impairment (MCI) who were examined for conversion to dementia for up to 3 years. Plasma Ptau-181 was measured using the ultrasensitive Quanterix HD-X assay. Results Among 476 MCI participants, 67% were amyloid positive (Aβ+) at baseline and 30% developed dementia. Plasma P-tau181 was higher in the Aβ+ population (3.9 (SD 1.4) vs 2.6 (SD 1.4) pg/mL) and in MCI that converted to dementia (3.8 (SD 1.5) vs 2.9 (SD 1.4) pg/mL). The addition of plasma P-tau181 to a logistic regression model combining age, sex, APOEε4 status and Mini Mental State Examination improved predictive performance (areas under the curve 0.691–0.744 for conversion and 0.786–0.849 for Aβ+). The Kaplan-Meier curve of conversion to dementia, according to the tertiles of plasma P-tau181, revealed a significant predictive value (Log rank p<0.0001) with an HR of 3.8 (95% CI 2.5 to 5.8). In addition, patients with plasma P-Tau(181) ≤2.32 pg/mL had a conversion rate of less than 20% over a 3-year period. Using a linear regression approach, chronic kidney disease, creatinine and estimated glomerular filtration rate were independently associated with plasma P-tau181 concentrations. Conclusions Plasma P-tau181 effectively detects Aβ+ status and conversion to dementia, confirming the value of this blood biomarker for the management of AD. However, renal function significantly modifies its levels and may thus induce diagnostic errors if not taken into account.Lire moins >
Lire la suite >Objectives Plasma P-tau181 is an increasingly established diagnostic marker for Alzheimer’s disease (AD). Further validation in prospective cohorts is still needed, as well as the study of confounding factors that could influence its blood level. Methods This study is ancillary to the prospective multicentre Biomarker of AmyLoid pepTide and AlZheimer’s diseAse Risk cohort that enrolled participants with mild cognitive impairment (MCI) who were examined for conversion to dementia for up to 3 years. Plasma Ptau-181 was measured using the ultrasensitive Quanterix HD-X assay. Results Among 476 MCI participants, 67% were amyloid positive (Aβ+) at baseline and 30% developed dementia. Plasma P-tau181 was higher in the Aβ+ population (3.9 (SD 1.4) vs 2.6 (SD 1.4) pg/mL) and in MCI that converted to dementia (3.8 (SD 1.5) vs 2.9 (SD 1.4) pg/mL). The addition of plasma P-tau181 to a logistic regression model combining age, sex, APOEε4 status and Mini Mental State Examination improved predictive performance (areas under the curve 0.691–0.744 for conversion and 0.786–0.849 for Aβ+). The Kaplan-Meier curve of conversion to dementia, according to the tertiles of plasma P-tau181, revealed a significant predictive value (Log rank p<0.0001) with an HR of 3.8 (95% CI 2.5 to 5.8). In addition, patients with plasma P-Tau(181) ≤2.32 pg/mL had a conversion rate of less than 20% over a 3-year period. Using a linear regression approach, chronic kidney disease, creatinine and estimated glomerular filtration rate were independently associated with plasma P-tau181 concentrations. Conclusions Plasma P-tau181 effectively detects Aβ+ status and conversion to dementia, confirming the value of this blood biomarker for the management of AD. However, renal function significantly modifies its levels and may thus induce diagnostic errors if not taken into account.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Date de dépôt :
2024-01-15T23:12:21Z
2024-12-04T10:07:54Z
2024-12-04T10:07:54Z
Annexes
- document
- Accès libre
- Source du fichier principal
- Accéder au document